Slammed by more deaths, Seattle Genetics scraps a PhIII study and pulls back (again) on vadastuximab
Just three months after the FDA lifted a clinical hold on its late-stage cancer drug vadastuximab talirine (SGN-CD33A), the biotech abruptly scrapped a Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
